Physician profile
Edward Riegel
NPI 1669570487
$3,599.69
in general payments reported to CMS, 2019-2025
21 companies · $667 in 2025
The $667 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $71.77 · 2021: $162 · 2022: $631 · 2023: $876 · 2024: $690 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,293.19 | 2022-2025 | |
| Alcon Vision LLC | $546.71 | 2023-2025 | Clareon, Eysuvis, Tryptyr |
| Allergan, INC. | $344.43 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $257.30 | 2019-2022 | |
| Shire North American Group INC | $187.89 | 2019 | |
| New World Medical,INC. | $137.01 | 2022 | |
| Rxsight INC | $130.96 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Biotissue Holdings INC. | $123.65 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $123.50 | 2020-2025 | |
| Bausch & Lomb Americas INC. | $99.38 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $98.92 | 2022-2023 | Tyrvaya |
| Amgen INC. | $46.15 | 2024 | Tepezza |
| Halozyme INC | $38.47 | 2023-2025 | Hylenex Recombinant |
| Astellas Pharma US INC | $29.98 | 2025 | Izervay |
| Eyevance Pharmaceuticals LLC | $29.09 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $28.07 | 2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Mallinckrodt Hospital Products INC. | $20.12 | 2024 | Acthar |
| Genentech USA, INC. | $20.02 | 2025 | Susvimo |
| Regeneron Healthcare Solutions, INC. | $19.23 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.16 | 2021 | |
| Sight Sciences, INC. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Riegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.